目的：系统评价亚洲青少年儿童中低度近视使用0.01%阿托品眼液1a后屈光度及眼轴的变化。 方法：检索PubMed、the Cochrane Library、Embase、CNKI、CBM、VIP和WanFang Data数据库中的随机对照试验，语言限定为中文或英文。对纳入文献采用《Cochrane干预措施系统评价手册》中偏倚风险评价工具进行质量评价； 对纳入文献的发表偏倚采用Egger检验进行检测； 采用Review Manager 5.4软件进行Meta分析。 结果：共有7篇文献符合纳入标准，包含979例研究对象(试验组440例，对照组539例)。Meta分析结果显示：0.01%阿托品在控制中低度近视儿童屈光度增加的方面优于对照组[WMD=0.50，95%CI(0.37，0.64)，P<0.00001]； 0.01%阿托品在控制中低度近视儿童眼轴增长的方面优于对照组[WMD=-0.20，95%CI(-0.30，-0.10)，P=0.0001]。 结论：浓度为0.01%阿托品可有效控制亚洲青少年儿童中低度近视屈光度的增加与眼轴的增长。

AIM:To evaluate the effects of 0.01% atropine for Asian adolescents and children of low and medium myopia in diopter and axial length. METHODS:We searched on PubMed, the Cochrane Library, Embase, CNKI, CBM, VIP and WanFang Data database for randomized controlled trials(RCTs). The published languages were limited to Chinese and English. The risk bias tool provided by the Cochrane cooperation scale was used to assess the risk bias of included studies of RCTs. The published biases of included studies were assessed by the Egger's test. Meta-analysis was performed with Review Manager 5.4. RESULTS: Seven randomized controlled trials with a total of 979 subjects were included(440 in the 0.01% atropine group and 539 in the control group). The Meta-analysis showed that 0.01% atropine has a better effect than the control group in controlling the diopter growth in moderate and low myopia of Asian adolescents and children. The difference between the two groups was statistically significant [WMD=0.50, 95%CI (0.37, 0.64), P<0.00001]. And the results also indicated that the change in axial length of 0.01% atropine was significantly less than the control group, the difference between the two groups was statistically significant [WMD= -0.20, 95%CI (-0.30, -0.10), P=0.0001].CONCLUSION: Based on the available evidence, 0.01% atropine offer in controlling axial length and diopter growth of low and medium myopia in Asian adolescents and children.

四川省科技厅计划项目(No.2015JY0263); 四川省医学科研课题(No.S18034); 南充市科技项目市校合作战略合作专项(No.18SXHZ0386)